Holen Sie sich die Stockscreener-App
2.64
1.93%
0.05
Handel nachbörslich:
2.64
Schlusskurs vom Vortag:
$2.59
Offen:
$2.5831
24-Stunden-Volumen:
10,133
Relative Volume:
0.05
Marktkapitalisierung:
$30.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.15M
KGV:
-8.6501
EPS:
-0.3052
Netto-Cashflow:
$-2.23M
1W Leistung:
+3.13%
1M Leistung:
-22.35%
6M Leistung:
+45.86%
1J Leistung:
-25.42%
1-Tages-Spanne:
$2.52
$2.64
1-Wochen-Bereich:
$2.32
$2.64
52-Wochen-Spanne:
$1.20
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Firmenname
Cytomed Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GDTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
2.64 | 30.47M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten
CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 13.7% – Here’s What Happened - Defense World
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India - Yahoo Finance
CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India - Yahoo Finance
SunAct & CytoMed join hands for Ph 2 clinical trials of innovative cancer therapy in India - BSA bureau
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga
CytoMed Therapeutics Limited Signs Business & Research Collaboration Agreement with Sunact Cancer Institute Private Limited to Advance Use of Allogeneic Off-The-Shelf Gamma Delta T Cells for Treatment of Solid Cancers in Proposed Phase 2 Clinical Tr - Marketscreener.com
CytoMed and SunAct partner for cancer immunotherapy trials - Investing.com
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in - Marketscreener.com
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - Simply Wall St
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Co-Chief Executive Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Director and Chief Operating Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics : Organisation and personnel changes Form 6 K - Marketscreener.com
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Simply Wall St
CytoMed Therapeutics : Update on Clinical Milestone CytoMed Therapeutics Announces First Patient Dosed in its First in Human Phase I Clinical Trial of Allogeneic CAR Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematologica - Marketscreener.com
CytoMed Therapeutics Limited Announces First Patient Dosed in Its First-In-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Marketscreener.com
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Simply Wall St
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
Osteopore Partners with CytoMed in Regenerative Medicine - TipRanks
CytoMed begins clinical trial for innovative cancer therapy - Investing.com
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank - Marketscreener.com
Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - TipRanks
CytoMed Launches Innovative CAR-T Cell Trial - TipRanks
CytoMed begins clinical trial for innovative cancer therapy By Investing.com - Investing.com South Africa
CytoMed Therapeutics’ first-in-human Phase I ANGELICA - GlobeNewswire
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - StockTitan
CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine - Yahoo Finance
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank - The Manila Times
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
GDTCCytoMed Therapeutics Limited Ordinary Shares Latest Stock News & Market Updates - StockTitan
CYTOMED THERAPEUTICS : AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K - Marketscreener.com
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates - Yahoo Finance
Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire
CytoMed Therapeutics Limited acquired the licence and certain assets of Cellsafe International Sdn Bhd from Cellsafe Biotech Group for MYR 2.3 million. - Marketscreener.com
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewswire
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Emergence of Cell and Gene Therapy Community in Singapore - BSA bureau
Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2031 - InsightAce Analytic
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - Yahoo Finance
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies - Marketscreener.com
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance
GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology - PR Newswire
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire
Cytomed Therapeutics Limited (GDTC-Q) QuotePress Release - The Globe and Mail
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - Investing.com South Africa
CytoMed Therapeutics Granted Patent in China for Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Investing.com South Africa
Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US - PR Newswire
Finanzdaten der Cytomed Therapeutics Ltd-Aktie (GDTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):